Biogen Inc.
(NASDAQ: BIIB)

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

175.370 -

+0.540 (+0.31%)
Range 173.510 - 176.739   (1.86%)
Open 174.880
Previous Close 174.830
Bid Price 175.370
Bid Volume 12
Ask Price 175.620
Ask Volume 5
Volume 196,869
Value 24,546,106
Remark -
Delayed prices. Updated at 29 Jan 2026 23:54.
Data powered by
View All Events

About Biogen

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company�s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company acquired from the Dompe Group the noncontrolling interests in its joint venture sales affiliates in Italy and Switzerland. In April 2013, Elan Corporation, plc closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Loading Chart...

Please login to view stock data and analysis